Alcoholic hepatitis
disease diseaseOn this page
Also known as acute alcoholic hepatitis
Summary
Alcoholic hepatitis (MONDO:0001505) is a disease and 96 clinical trials. Top therapeutic interventions include pentoxifylline, acetylcysteine, and anakinra. A subtype of hepatitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 96
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | alcoholic hepatitis |
| Mondo ID | MONDO:0001505 |
| EFO | EFO:1001345 |
| MeSH | D006519 |
| DOID | DOID:12351 |
| ICD-10-CM | K70.1 |
| ICD-11 | 229221394 |
| NCIT | C34684 |
| SNOMED CT | 235875008 |
| UMLS | C0019187 |
| MedGen | 42422 |
| Is cancer (heuristic) | no |
Also known as: acute alcoholic hepatitis · alcoholic Hepatitis · alcoholic hepatitis
Disease family
This is a subtype of hepatitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › liver disorder › hepatitis › alcoholic hepatitis
Related subtypes (8): drug-induced hepatitis, granulomatous hepatitis, hepatic tuberculosis, viral hepatitis, metabolic dysfunction-associated steatohepatitis, autoimmune hepatitis, fulminant viral hepatitis, idiopathic peliosis hepatis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
No drug has an approved disease-direct ChEMBL indication for this disease.
18 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Acetylcysteine | Phase 3 |
| Amoxicillin | Phase 3 |
| Filgrastim | Phase 3 |
| Pentoxifylline | Phase 3 |
| Prednisolone | Phase 3 |
| Rifaximin | Phase 3 |
| Anakinra | Phase 2 |
| Arginine | Phase 2 |
| Canakinumab | Phase 2 |
| Methylprednisolone | Phase 2 |
| Mycophenolate Mofetil | Phase 2 |
| Obeticholic Acid | Phase 2 |
| Prednisone | Phase 2 |
| Pyridoxine | Phase 2 |
| Rilonacept | Phase 2 |
| Selonsertib | Phase 2 |
| Zinc Ion | Phase 2 |
| Zinc Sulfate | Phase 2 |
Clinical trials & evidence
Clinical trials
Clinical trials: 96.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 50 |
| PHASE2 | 19 |
| PHASE3 | 15 |
| PHASE4 | 5 |
| EARLY_PHASE1 | 3 |
| PHASE1/PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01413360 | PHASE4 | COMPLETED | The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients |
| NCT02161653 | PHASE4 | COMPLETED | Metadoxine as a Therapy for Severe Alcoholic Hepatitis |
| NCT02971306 | PHASE4 | UNKNOWN | G-CSF Plus NAC In Severe Alcoholic Hepatitis |
| NCT03703674 | PHASE4 | UNKNOWN | GCSF in Alcoholic Hepatitis |
| NCT05840640 | PHASE4 | COMPLETED | Granulocyte Colony Stimulating Factor Four Week Plus N-Acetyl Cysteine in Severe Alcoholic Hepatitis |
| NCT02473341 | PHASE3 | ACTIVE_NOT_RECRUITING | Gut-Liver Axis Modulation With IgG-Enriched Immunotherapy in Severe Alcohol-Associated Hepatitis |
| NCT06919458 | PHASE3 | RECRUITING | Short Course Steroids in Alcohol Associated Hepatitis |
| NCT06956482 | PHASE3 | NOT_YET_RECRUITING | PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis |
| NCT00863785 | PHASE3 | COMPLETED | Treatment of Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone |
| NCT00962442 | PHASE3 | COMPLETED | N-Acetylcysteine in Severe Acute Alcoholic Hepatitis |
| NCT01214226 | PHASE3 | COMPLETED | Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis |
| NCT01455337 | PHASE3 | UNKNOWN | Short-term Survival in Patients With Severe Alcoholic Hepatitis Treated With Steroid Versus Pentoxifylline |
| NCT01471028 | PHASE3 | COMPLETED | Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure |
| NCT01809132 | PHASE2/PHASE3 | COMPLETED | Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis |
| NCT01829347 | PHASE3 | TERMINATED | To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure |
| NCT02281929 | PHASE3 | COMPLETED | Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone |
| NCT02442180 | PHASE3 | TERMINATED | Efficacy and Safety of G-CSF in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid |
| NCT02485106 | PHASE3 | UNKNOWN | Rifaximin Use in Severe Alcoholic Hepatitis |
| NCT02612428 | PHASE3 | TERMINATED | Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD |
| NCT03069300 | PHASE3 | UNKNOWN | N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis |
| NCT04758806 | PHASE3 | UNKNOWN | Fecal Microbial Transplantation in Severe Alcoholic Hepatitis |
| NCT05006430 | PHASE1/PHASE2 | RECRUITING | Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis |
| NCT06307522 | PHASE2 | NOT_YET_RECRUITING | MRG-001 in Patients With Alcoholic Hepatitis |
| NCT06890039 | PHASE2 | NOT_YET_RECRUITING | A-TANGO Phase 2 Study |
| NCT00200746 | PHASE2 | WITHDRAWN | Treatment of Alcohol-Related Hepatitis With Arginine |
| NCT00851981 | PHASE2 | COMPLETED | Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease |
| NCT01903798 | PHASE2 | COMPLETED | A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis |
| NCT01912404 | PHASE2 | TERMINATED | Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy |
| NCT01937130 | PHASE2 | TERMINATED | Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF |
| NCT02019056 | PHASE2 | COMPLETED | Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis |
| NCT02039219 | PHASE2 | TERMINATED | Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) |
| NCT02116556 | PHASE2 | UNKNOWN | Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis |
| NCT02655510 | PHASE1/PHASE2 | COMPLETED | Use of F-652 in Patients With Alcoholic Hepatitis |
| NCT02776059 | PHASE2 | COMPLETED | Pegfilgrastim in Patients With Alcoholic Hepatitis |
| NCT02854631 | PHASE2 | COMPLETED | Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH) |
| NCT03432260 | PHASE2 | COMPLETED | A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis |
| NCT03775109 | PHASE2 | COMPLETED | IL-1 Signal Inhibition in Alcoholic Hepatitis |
| NCT03829683 | PHASE2 | COMPLETED | Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis |
| NCT03917407 | PHASE2 | COMPLETED | DUR-928 in Patients With Alcoholic Hepatitis |
| NCT04072822 | PHASE2 | COMPLETED | Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PENTOXIFYLLINE | 4 | 3 |
| ACETYLCYSTEINE | 4 | 2 |
| ANAKINRA | 4 | 2 |
| RIFAXIMIN | 4 | 2 |
| CANAKINUMAB | 4 | 1 |
| DIGOXIN | 4 | 1 |
| GENTAMICIN | 4 | 1 |
| HYALURONATE SODIUM | 4 | 1 |
| PROTHROMBIN | 4 | 1 |
| PYRIDOXINE | 4 | 1 |
| RILONACEPT | 4 | 1 |
| ZINC SULFATE | 4 | 1 |
| SELONSERTIB | 3 | 2 |
| ADEMETIONINE | 3 | 1 |
| ARGININE | 3 | 1 |
| RESATORVID | 3 | 1 |
| ZINC ION | 3 | 1 |
| EMRICASAN | 2 | 2 |
| LARSUCOSTEROL | 2 | 2 |
| EFLEPEDOCOKIN ALFA | 2 | 1 |
| CHEMBL5435500 | 0 | 3 |
| CHEMBL5220618 | 0 | 2 |
| CHEMBL423707 | 0 | 1 |
| CHEMBL1201279 | 0 | 1 |
| CHEMBL5421678 | 0 | 1 |
| GENTAMICIN C1 | 0 | 1 |